PRTA biotech catalysts & pipeline

PROTHENA CORP PUBLIC LTD CO · Data as of 2026-09-08

Upcoming catalysts

PRX019 — Topline data

2026

Prothena is conducting a Phase 1 first-in-human clinical trial to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of single ascending and multiple doses in healthy adults with completion expected in 2026

Source filing

coramitug (formerly PRX004) — other

Late 2026

Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb

Source filing

PRX019 — Regulatory decision

Late 2026

Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026

Source filing

coramitug (formerly PRX004) — Topline data

2027

Open-label study ongoing to evaluate the biodistribution of 89Zr-coramitug and investigate the effects of coramitug on depleting TTR amyloid deposits in myocardial tissues using PET/CT imaging in participants with ATTR-CM; primary completion expected in 2027 (NCT07448623)

Source filing

moponetug — Topline data

1H 2027

Bristol Myers Squibb is conducting the Phase 2 TargetTau-1 clinical trial in approximately 310 patients with early Alzheimer's disease; primary completion expected in 1H 2027 (NCT06268886)

Source filing

coramitug (formerly PRX004) — Topline data

2029

Novo Nordisk is conducting the Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)

Source filing

prasinezumab — Topline data

2029

Roche is conducting the Phase 3 PARAISO clinical trial in approximately 900 participants with early-stage Parkinson's disease; primary completion expected in 2029 (NCT07174310)

Source filing

Explore the free biotech catalyst calendar